CONMED Management

Management Kriterienprüfungen 3/4

CONMED CEO ist Curt Hartman , ernannt in Jul 2014, hat eine Amtszeit von 10.33 Jahren. Die jährliche Gesamtvergütung beträgt $7.76M , bestehend aus 12.2% Gehalt und 87.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.3% der Aktien des Unternehmens, im Wert von MX$135.58M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.8 Jahre bzw. 9.3 Jahre.

Wichtige Informationen

Curt Hartman

Geschäftsführender

US$7.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	12.2%
Amtszeit als Geschäftsführer	10.3yrs
Eigentum des Geschäftsführers	0.3%
Durchschnittliche Amtszeit des Managements	5.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	9.3yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Curt Hartman im Vergleich zu den Einnahmen von CONMED verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	US$132m
Jun 30 2024	n/a	n/a	US$99m
Mar 31 2024	n/a	n/a	US$82m
Dec 31 2023	US$8m	US$950k	US$64m
Sep 30 2023	n/a	n/a	US$58m
Jun 30 2023	n/a	n/a	US$88m
Mar 31 2023	n/a	n/a	-US$94m
Dec 31 2022	US$8m	US$946k	-US$81m
Sep 30 2022	n/a	n/a	-US$83m
Jun 30 2022	n/a	n/a	-US$114m
Mar 31 2022	n/a	n/a	US$68m
Dec 31 2021	US$9m	US$918k	US$63m
Sep 30 2021	n/a	n/a	US$62m
Jun 30 2021	n/a	n/a	US$54m
Mar 31 2021	n/a	n/a	US$13m
Dec 31 2020	US$6m	US$888k	US$10m
Sep 30 2020	n/a	n/a	US$311k
Jun 30 2020	n/a	n/a	US$431k
Mar 31 2020	n/a	n/a	US$34m
Dec 31 2019	US$6m	US$842k	US$29m
Sep 30 2019	n/a	n/a	US$29m
Jun 30 2019	n/a	n/a	US$28m
Mar 31 2019	n/a	n/a	US$31m
Dec 31 2018	US$5m	US$791k	US$41m
Sep 30 2018	n/a	n/a	US$72m
Jun 30 2018	n/a	n/a	US$73m
Mar 31 2018	n/a	n/a	US$71m
Dec 31 2017	US$3m	US$753k	US$55m

Vergütung im Vergleich zum Markt: CurtDie Gesamtvergütung ($USD7.76M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt MX ($USD700.99K).

Entschädigung vs. Einkommen: CurtDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Curt Hartman (60 yo)

10.3yrs

Amtszeit

US$7,764,615

Vergütung

Mr. Curt R. Hartman serves as the Director of CONMED Corporation since October 31, 2024 and Chief Executive Officer and President of CONMED Corporation since November 09, 2014, He served as Chairman of the...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Curt Hartman	President	10.3yrs	US$7.76m	0.30% MX$ 135.6m
Todd Garner	Executive VP	6.8yrs	US$2.87m	0.00073% MX$ 327.0k
Patrick Beyer	Chief Operating Officer	less than a year	US$3.30m	0.035% MX$ 15.7m
Richard Glaze	Chief Information Officer	no data	keine Daten	keine Daten
Hollie Foust	General Counsel & Corporate Secretary	no data	keine Daten	keine Daten
Peter Shagory	Executive Vice President of Strategy & Corporate Development	9.5yrs	keine Daten	0.012% MX$ 5.4m
Shanna Cotti-Osmanski	Executive VP of Information Technology & CIO	4.7yrs	keine Daten	keine Daten
John Ferrell	Executive Vice President of Human Resources	1.9yrs	keine Daten	0.0023% MX$ 1.0m
David Murray	President of ConMed Electrosurgery	20.3yrs	US$572.33k	keine Daten
Johonna Pelletier	VP of Tax & Treasurer	9.6yrs	keine Daten	0.0043% MX$ 1.9m
Kimberly Lockwood	Interim Corporate Controller	less than a year	keine Daten	keine Daten

5.8yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: CNMD *Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Curt Hartman	President	10.7yrs	US$7.76m	0.30% MX$ 135.6m
John Workman	Independent Director	9.3yrs	US$257.37k	0.066% MX$ 29.6m
David Bronson	Independent Director	9.3yrs	US$264.87k	0.054% MX$ 24.3m
Brian Concannon	Independent Director	11.3yrs	US$257.37k	0.031% MX$ 14.0m
LaVerne Council	Independent Director	4.9yrs	US$257.37k	0.012% MX$ 5.2m
Martha Aronson	Independent Chair of the Board	8.8yrs	US$292.37k	0.045% MX$ 20.2m
Charles Farkas	Independent Director	10.3yrs	US$249.87k	0.066% MX$ 29.5m
Barbara Schwarzentraub	Independent Director	5.2yrs	US$264.87k	0.017% MX$ 7.7m

9.3yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrener Vorstand: CNMD *Die Vorstandsmitglieder gelten als erfahren (9.3 Jahre durchschnittliche Amtszeit).

CONMED Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

CONMED Corporation Announces Chief Executive Officer Changes

Insufficient new directors

CONMED Corporation Announces Termination of Stanley W. (Bill) Peters as President, Advanced Surgical & Advanced Endoscopic Technologies, Effective August 31, 2024

Insufficient new directors

Chief Operating Officer recently bought Mex$3.5m worth of stock

Insufficient new directors

Recent updates

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

CONMED Corporation Announces Chief Executive Officer Changes

CONMED Corporation to Report Q3, 2024 Results on Oct 30, 2024

Upcoming dividend of US$0.20 per share

Insufficient new directors

CONMED Corporation Announces Termination of Stanley W. (Bill) Peters as President, Advanced Surgical & Advanced Endoscopic Technologies, Effective August 31, 2024

Second quarter 2024 earnings released: EPS: US$0.97 (vs US$0.45 in 2Q 2023)

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

Insufficient new directors

CONMED Corporation to Report Q2, 2024 Results on Jul 31, 2024

Upcoming dividend of US$0.20 per share

First quarter dividend of US$0.20 announced

CONMED Corporation Declares Quarterly Cash Dividend, Payable on July 5, 2024

Chief Operating Officer recently bought Mex$3.5m worth of stock

Insufficient new directors

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

Insufficient new directors

CONMED Corporation, Annual General Meeting, May 22, 2024

CONMED Corporation, Annual General Meeting, May 22, 2024

CONMED Corporation to Report Q1, 2024 Results on Apr 24, 2024

CONMED Corporation Declares Quarterly Cash Dividend, Payable on April 5, 2024

CONMED Corporation Provides Financial Guidance for the Full Year 2024

CONMED Corporation Announces Quarterly Cash Dividend, Payable on January 5, 2024

Insufficient new directors

CONMED Corporation Updates Third Quarter Guidance for 2023

Insufficient new directors

CONMED Corporation to Report Q3, 2023 Results on Oct 25, 2023

Insufficient new directors

CONMED Corporation Announces Quarterly Cash Dividend, Payable on October 5, 2023

Second quarter 2023 earnings released: EPS: US$0.45 (vs US$5.65 loss in 2Q 2022)

CONMED Corporation Revises Earnings Guidance for the Full Year 2023

Insufficient new directors

CONMED Corporation to Report Q2, 2023 Results on Jul 26, 2023

CONMED Corporation Announces Quarterly Cash Dividend, Payable on July 5, 2023

Insufficient new directors

Insufficient new directors

Full year 2022 earnings released: US$2.68 loss per share (vs US$2.15 profit in FY 2021)

CONMED Corporation Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

CONMED Corporation to Report Q4, 2022 Results on Feb 02, 2023

CONMED Corporation Announces Management Changes

CONMED Corporation Announces Quarterly Cash Dividend, Payable on January 5, 2023

Insufficient new directors

CONMED Corporation Provides Revenue Guidance for the Full Year 2023

Insufficient new directors

Now 24% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$1.51 (vs US$0.51 in 3Q 2021)

CONMED Corporation Revises Earnings Guidance for the Full Year 2022

Now 21% undervalued

CONMED Corporation to Report Q3, 2022 Results on Oct 26, 2022

Insufficient new directors

Chairman of the Board recently sold Mex$6.6m worth of stock

Now 21% undervalued after recent price drop

Upcoming dividend of US$0.20 per share

CONMED Corporation Announces Quarterly Cash Dividend, Payable on October 5, 2022

CONMED Corporation (NYSE:CNMD) completed the acquisition of Biorez, Inc.

CONMED Corporation (NYSE:CNMD) completed the acquisition of Biorez, Inc.

CONMED Corporation (NYSE:CNMD) has entered into a definitive agreement to acquire Biorez, Inc. for $250 million.

CONMED Corporation (NYSE:CNMD) has entered into a definitive agreement to acquire Biorez, Inc. for $250 million.

Second quarter 2022 earnings released: US$5.65 loss per share (vs US$0.46 profit in 2Q 2021)

CONMED Corporation Revises Earnings Guidance for the Full Year 2022

CONMED Corporation to Report Q2, 2022 Results on Jul 27, 2022

CONMED Corporation(NYSE:CNMD) dropped from Russell 2000 Dynamic Index

Now 20% undervalued

CONMED Corporation (NYSE:CNMD) completed the acquisition of In2Bones Global, Inc.

Upcoming dividend of US$0.20 per share

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit